EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Gastrointestinal adverse effects of GLP‐1 receptor agonists and dual GIP/GLP‐1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents

Vikash Singhani iD, Muhammad Ehsan, Sara Valencia, Ahmed Nadeem, Eisha Moazzam, Winfield Scott Butsch, Samita Garg iD

Nutrition in Clinical Practice · 2026

DOI: 10.1002/ncp.70180 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nutrition in Clinical Practice, 2026. Verfasst von Vikash Singhani und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Hepatology and Nutrition, Digestive Disease Institute, Cleveland Clinic, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Gastrointestinal Diseases, Hypoglycemic Agents, Gastric Inhibitory Polypeptide. Die Arbeit nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and dual glucose‐dependent insulinotropic polypeptide (GIP)/GLP‐1 receptor agonists have transformed the management of type 2 diabetes and obesity. Gastrointestinal (GI) adverse events are the most common limitation of these therapies and a leading cause of discontinuation.

Methods

This narrative expert review synthesizes evidence from randomized controlled trials, observational studies, meta‐analyses, and pharmacovigilance data to characterize the incidence, mechanisms, and clinical implications of GI adverse effects across approved agents and late‐stage pipeline therapies.

Results

Nausea, vomiting, diarrhea, and constipation are established class effects, occurring in approximately 30%–50% of patients, typically during initiation and dose escalation. These events are generally mild to moderate and manageable with dose titration and dietary modification. Mechanisms include delayed gastric emptying, central activation of emetic pathways, altered intestinal motility, and physiologic effects of rapid weight loss itself. Randomized trial data are reassuring for acute pancreatitis, with no class‐level excess risk demonstrated; pharmacovigilance signals are most plausibly explained by diagnostic misclassification rather than true causal risk. Cholelithiasis shows a probable class‐level association, substantially mediated by weight loss rather than direct receptor signaling. Peri‐procedural data show increased residual gastric volume without confirmed aspiration events. Preliminary data on late‐stage pipeline agents (retatrutide, survodutide, and cagrilintide‐semaglutide) suggest a similar GI adverse event profile to approved agents, though evidence remains largely limited.

Conclusion

GI adverse events with GLP‐1‐based therapies are predictable and manageable. A proactive, patient‐centered approach is essential to optimize adherence, safety, and clinical outcomes as newer agents expand the therapeutic landscape.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsGastrointestinal DiseasesHypoglycemic AgentsGastric Inhibitory PolypeptideReceptors, Gastrointestinal HormoneHumansDiabetes Mellitus, Type 2ObesityRandomized Controlled Trials as TopicTirzepatide

Stichwörter der Autor:innen

GLP‐1 receptor agonistsdiabetes mellitusdual GIP/GLP‐1 receptor agonistsgastrointestinal adverse eventsobesityorforglipronsemaglutidetirzepatide

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsGastric Inhibitory Polypeptidegastric inhibitory polypeptide receptorReceptors, Gastrointestinal HormoneTirzepatide

Autor:innen und Institutionen

  • Department of Gastroenterology, Hepatology and Nutrition, Digestive Disease Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
  • Department of Internal Medicine, King Edward Medical University, Lahore, Pakistan.
  • Department of Surgery, Digestive Disease Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Department of Internal Medicine and Geriatrics, Primary Care Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Novo Nordisk, Copenhagen, Denmark.

ORCID-Profile: Vikash Singhani, Samita Garg

Zitieren

APA

Singhani, V., Ehsan, M., Valencia, S., Nadeem, A., Moazzam, E., Butsch, W. S., & Garg, S. (2026). Gastrointestinal adverse effects of GLP‐1 receptor agonists and dual GIP/GLP‐1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents. Nutrition in Clinical Practice. https://doi.org/10.1002/ncp.70180

Vancouver

Singhani V, Ehsan M, Valencia S, Nadeem A, Moazzam E, Butsch WS, et al. Gastrointestinal adverse effects of GLP‐1 receptor agonists and dual GIP/GLP‐1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents. Nutrition in Clinical Practice. 2026. doi:10.1002/ncp.70180

BibTeX
@article{Singhani2026,
  author = {Singhani, Vikash and Ehsan, Muhammad and Valencia, Sara and Nadeem, Ahmed and Moazzam, Eisha and Butsch, Winfield Scott and Garg, Samita},
  title = {Gastrointestinal adverse effects of GLP‐1 receptor agonists and dual GIP/GLP‐1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents},
  journal = {Nutrition in Clinical Practice},
  year = {2026},
  doi = {10.1002/ncp.70180}
}
Kostenlos starten →